KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Gains from Investment Securities (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Gains from Investment Securities for 6 consecutive years, with $31.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 1762.34% year-over-year to $31.1 million, compared with a TTM value of $30.1 million through Dec 2025, up 53.43%, and an annual FY2025 reading of $30.1 million, up 53.43% over the prior year.
  • Gains from Investment Securities was $31.1 million for Q4 2025 at AbCellera Biologics, up from -$1.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $31.1 million in Q4 2025 and bottomed at -$23.1 million in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $3.8 million, with a median of $3.1 million recorded in 2021.
  • Peak annual rise in Gains from Investment Securities hit 43453.57% in 2021, while the deepest fall reached 5875.12% in 2021.
  • Year by year, Gains from Investment Securities stood at $27.9 million in 2021, then tumbled by 182.71% to -$23.1 million in 2022, then surged by 55.81% to -$10.2 million in 2023, then soared by 116.35% to $1.7 million in 2024, then surged by 1762.34% to $31.1 million in 2025.
  • Business Quant data shows Gains from Investment Securities for ABCL at $31.1 million in Q4 2025, -$1.7 million in Q3 2025, and -$1.2 million in Q2 2025.